Skip to main content
Fig. 2 | BMC Pulmonary Medicine

Fig. 2

From: Osimertinib versus afatinib in patients with T790M-positive, non-small-cell lung cancer and multiple central nervous system metastases after failure of initial EGFR-TKI treatment

Fig. 2

Kaplan–Meier curves for OS. The median OS was 13.7 months (95% CI, 11.1–14.8) for OSI and 9.6 months (95% CI, 8.4–10.2) for AFA. A significant difference was observed in the median OS between groups. *HR was calculated using the Cox proportional hazards model, with age, sex and time span of smoking history as covariates and OSI/AFA therapy as the time-dependent factor. With respect to OS, the results were analysed using the log-rank test (p = 0.0160)

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us